| abstract |
The present disclosure provides an ActRII antagonist, e.g., the ActRIIA and/or ActRIIB antagonist, e.g., an anti-ActRII receptor antibody or antigen-binding fragment thereof, e.g., bimagrumab, for treating or preventing liver disease or disorder in a subject in need thereof. The present disclosure also relates to pharmaceutical combinations comprising such ActRII antagonists and at least one further therapeutic agent in the treatment or prevention of liver disease or disorder. |